ATLAS and FLAIR were clinical trials designed to evaluate the efficacy and safety of long-acting CABENUVA in adult (≥18 years) patients with HIV-1 who were virologically suppressed at time …

Explore ATLAS-2M efficacy and safety data, including study design and baseline characteristics for the CABENUVA (cabotegravir; rilpivirine) study. For US HCPs only. Learn more about the …

Atlas all-terrain vehicle - Versatility, Passage, Ease of Management, Maneuverability. Order an all-terrain vehicle from the manufacturer at the best prices +38 073 009-9-000

Advances in antiretroviral (ARV) treatment and a better understanding of HIV drug resistance have made it possible to consider switching a person with HIV from an effective ARV regimen …

Mar 4, 2020 · Here we report the 48-week (primary end point) results of the phase 3 Antiretroviral Therapy as Long Acting Suppression (ATLAS) trial, the purpose of which was to establish …

48-week data from the Phase III ATLAS study and FLAIR study, demonstrating Cabenuva’s safety and efficacy as maintenance therapy with intramuscular dosing every four weeks, have been …

Dec 19, 2020 · Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non …

Feb 18, 2021 · Two Phase 3 trials (ATLAS and FLAIR) that enrolled almost 1,200 participants with HIV evaluated the safety and efficacy of once-monthly IM injections of CAB and RPV. …

ATLAS-2M is a multicenter, Phase 3b, randomized, open-label study investigating cabotegravir + rilpivirine long- acting (CAB + RPV LA) dosed every 8 weeks (Q8W) and every 4 weeks (Q4W) …

Jan 1, 2015 · In April 2019, the U.S. Food and Drug Administration approved a combination pill comprising the integrase inhibitor dolutegravir (DTG), 50 mg, and the NRTI lamivudine (3TC), …